Results 1 to 10 of about 416,036 (340)
Ototoxicity of cisplatin [PDF]
International Journal of Andrology, 1987 Ototoxicity is one of the unwanted side effects of cisplatin treatment. The first sign of hearing loss usually appears 3–4 days after the drug administration and occurs primarily in the higher frequencies. One hundred and eighty‐six women treated with a moderate dose of cisplatin (50 mg/m2every 4 weeks) for gynaecological cancer were studied.
Göran Laurell +3 more
openalex +4 more sources
Cisplatin Toxicity in Cats [PDF]
Journal of Veterinary Internal Medicine, 1987 Cisplatin (cis‐diamminedichloroplatinum; Platinol, Bristol, Syracuse, NY) was administered to 11 cats, divided into three groups of experimental and clinical patients. In group 1, cisplatin was administered at a dose of 60 mg/m2 to four cats. In an attempt to avoid renal toxicity, saline diuresis was induced by administering 0.9% saline solution ...
Deborah W. Knapp +4 more
openalex +4 more sources
Heliyon, 2023 Introduction: Bufei Huayu Decoction (BFHY) is a clinical prescription with reported efficacy in enhancing the therapeutic outcomes of chemotherapeutic agents for non-small cell lung cancer (NSCLC).
Yuan Feng +7 more
doaj +1 more source
Decitabine rescues cisplatin resistance in head and neck squamous cell carcinoma. [PDF]
PLoS ONE, 2014 Cisplatin resistance in head and neck squamous cell carcinoma (HNSCC) reduces survival. In this study we hypothesized that methylation of key genes mediates cisplatin resistance.
Chi T Viet +5 more
doaj +1 more source
Preferential Cochleotoxicity of Cisplatin [PDF]
Frontiers in Neuroscience, 2021 Cisplatin-induced ototoxicity in humans is more predominant in the cochlea than in the vestibule. Neither definite nor substantial vestibular dysfunction after cisplatin treatment has been consistently reported in the current literature. Inner ear hair cells seem to have intrinsic characteristics that make them susceptible to direct exposure to ...
Pattarawadee Prayuenyong +6 more
openaire +5 more sources
Protective Effect of Moderate-Intensity Continuous Training and High-Intensity Interval Training on Serum Levels of Oxidative Stress Parameters in Rats Treated with Cisplatin [PDF]
Journal of Mazandaran University of Medical Sciences, 2023 Background and purpose: Considering the antioxidant properties of physical activity, the aim of the present study was to investigate the effect of moderate-intensity continuous training (MICT) and high-intensity intermittent training (HIIT) on oxidative ...
Mohammad Parastesh +3 more
doaj +1 more source
Cisplatin ototoxicity histopathology [PDF]
Laryngoscope Investigative Otolaryngology, 2021 This study investigates the histopathological changes of the cochlea and vestibular end organs of a patient who received cisplatin for Hodgkin's lymphoma. He experienced acute high-frequency sensorineural hearing loss and tinnitus after receiving treatment.
Sarah E. Hodge +3 more
openaire +6 more sources
Scientific Reports, 2021 Cisplatin, one of the most active anticancer agents, is widely used in standard chemotherapy for various cancers. Cisplatin is more poorly tolerated than other chemotherapeutic drugs, and the main dose-limiting toxicity of cisplatin is its nephrotoxicity,
Masashi Arita +21 more
doaj +1 more source
Aspirin overcomes cisplatin resistance in lung cancer by inhibiting cancer cell stemness
Thoracic Cancer, 2020 Background Lung cancer is the leading cause of cancer death and is commonly treated by cisplatin. Although cisplatin treatment may initially be successful, its effectiveness usually reduces significantly in disease‐recurrent patients.
Maoyuan Zhao, Ting Wang, Zhouguang Hui
doaj +1 more source
Journal of Immunology Research, 2022 Objective. Evidence demonstrates that the immune microenvironment is extensively associated with chemotherapy response of ovarian cancer (OV). Herein, this study is aimed at establishing a cisplatin response prediction model for OV on the basis of immune
Ying Guo +4 more
doaj +1 more source